Clinical Trial Update: Oral Topotecan As A Radiosensitizing Agent In Rectal Cancer [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating oral topotecan as a radiosensitizing agent in rectal cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rectal Cancer
• Renal Cell Carcinoma

Drugs mentioned

• Topotecan (topotecan)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Carcinoma, Renal Cell | Phase 1 | Status: TERMINATED